634 related articles for article (PubMed ID: 16227959)
21. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
22. Tumoral angiogenesis: review of the literature.
Khosravi Shahi P; Fernández Pineda I
Cancer Invest; 2008 Feb; 26(1):104-8. PubMed ID: 18181052
[TBL] [Abstract][Full Text] [Related]
23. Understanding the importance of smart drugs in renal cell carcinoma.
Patard JJ; Rioux-Leclercq N; Fergelot P
Eur Urol; 2006 Apr; 49(4):633-43. PubMed ID: 16481093
[TBL] [Abstract][Full Text] [Related]
24. Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy.
Tonra JR; Hicklin DJ
Immunol Invest; 2007; 36(1):3-23. PubMed ID: 17190647
[TBL] [Abstract][Full Text] [Related]
25. Antiangiogenic therapy in the management of brain tumors: a clinical overview.
Kunnakkat S; Mathew M; Narayana A
Cancer Chemother Pharmacol; 2012 Sep; 70(3):353-63. PubMed ID: 22825032
[TBL] [Abstract][Full Text] [Related]
26. Colorectal cancer and antiangiogenic therapy: what can be expected in clinical practice?
Mancuso A; Sternberg CN
Crit Rev Oncol Hematol; 2005 Jul; 55(1):67-81. PubMed ID: 15890525
[TBL] [Abstract][Full Text] [Related]
27. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
Tortora G; Ciardiello F; Gasparini G
Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
[TBL] [Abstract][Full Text] [Related]
28. Targeting tumor angiogenesis.
Gaur P; Bose D; Samuel S; Ellis LM
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S12-9. PubMed ID: 19393831
[TBL] [Abstract][Full Text] [Related]
29. An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells.
Lacal PM; Ruffini F; Pagani E; D'Atri S
Int J Oncol; 2005 Dec; 27(6):1625-32. PubMed ID: 16273219
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics.
Sini P; Samarzija I; Baffert F; Littlewood-Evans A; Schnell C; Theuer A; Christian S; Boos A; Hess-Stumpp H; Foekens JA; Setyono-Han B; Wood J; Hynes NE
Cancer Res; 2008 Mar; 68(5):1581-92. PubMed ID: 18316624
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
Idbaih A; Ducray F; Sierra Del Rio M; Hoang-Xuan K; Delattre JY
Oncologist; 2008 Sep; 13(9):978-92. PubMed ID: 18779539
[TBL] [Abstract][Full Text] [Related]
32. Anti-VEGF therapy: a new approach to colorectal cancer therapy.
Carrato A; Gallego-Plazas J; Guillen-Ponce C
Expert Rev Anticancer Ther; 2006 Oct; 6(10):1385-96. PubMed ID: 17069524
[TBL] [Abstract][Full Text] [Related]
33. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.
Wachsberger P; Burd R; Dicker AP
Clin Cancer Res; 2003 Jun; 9(6):1957-71. PubMed ID: 12796357
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.
Tugues S; Koch S; Gualandi L; Li X; Claesson-Welsh L
Mol Aspects Med; 2011 Apr; 32(2):88-111. PubMed ID: 21565214
[TBL] [Abstract][Full Text] [Related]
35. Vascular endothelial growth factor receptors and the therapeutic targeting of angiogenesis in cancer: where do we go from here?
Bruce D; Tan PH
Cell Commun Adhes; 2011 Oct; 18(5):85-103. PubMed ID: 22017472
[TBL] [Abstract][Full Text] [Related]
36. Anti-angiogenic therapy against gastrointestinal tract cancers.
Iwasaki J; Nihira S
Jpn J Clin Oncol; 2009 Sep; 39(9):543-51. PubMed ID: 19531544
[TBL] [Abstract][Full Text] [Related]
37. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
Shibuya M
FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
[TBL] [Abstract][Full Text] [Related]
38. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis.
Saharinen P; Eklund L; Pulkki K; Bono P; Alitalo K
Trends Mol Med; 2011 Jul; 17(7):347-62. PubMed ID: 21481637
[TBL] [Abstract][Full Text] [Related]
39. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
40. The fight against cancer: the next round.
Doherty M
Drug Discov Today; 2004 Nov; 9(22):947-8. PubMed ID: 15539135
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
